Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

SEMIPARAMETRIC REGRESSION MODEL FOR RECURRENT BACTERIAL INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION.

Lee CH, Huang CY, DeFor TE, Brunstein CG, Weisdorf DJ, Luo X.

Stat Sin. 2019;29(3):1489-1509. doi: 10.5705/ss.202017.0397.

2.

Pediatric acute GVHD: clinical phenotype and response to upfront steroids.

MacMillan ML, Holtan SG, Rashidi A, DeFor TE, Blazar BR, Weisdorf DJ.

Bone Marrow Transplant. 2019 Sep 2. doi: 10.1038/s41409-019-0651-9. [Epub ahead of print]

PMID:
31477785
3.

Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients.

Pamukcuoglu M, Bhatia S, Weisdorf DJ, DeFor TE, Ustun C, Nayar M, Holtan SG, Jurdi NE, Thyagarajan B, Brunstein CG, Bachanova V, Warlick ED, Severseike B, Te HS, Lund T, Arora M.

Biol Blood Marrow Transplant. 2019 Aug 5. pii: S1083-8791(19)30502-6. doi: 10.1016/j.bbmt.2019.07.030. [Epub ahead of print]

PMID:
31394273
4.

Early E. casseliflavus gut colonization and outcomes of allogeneic hematopoietic cell transplantation.

Rashidi A, Ebadi M, Shields-Cutler RR, Kruziki K, Manias DA, Barnes AMT, DeFor TE, Ferrieri P, Young JH, Knights D, Blazar BR, Weisdorf DJ, Dunny GM.

PLoS One. 2019 Aug 8;14(8):e0220850. doi: 10.1371/journal.pone.0220850. eCollection 2019.

5.

Stress responses, M2 macrophages, and a distinct microbial signature in fatal intestinal acute graft-versus-host disease.

Holtan SG, Shabaneh A, Betts BC, Rashidi A, MacMillan ML, Ustun C, Amin K, Vaughn BP, Howard J, Khoruts A, Arora M, DeFor TE, Johnson D, Blazar BR, Weisdorf DJ, Wang J.

JCI Insight. 2019 Aug 8;5. pii: 129762. doi: 10.1172/jci.insight.129762.

6.

Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease.

Rashidi A, DeFor TE, Holtan SG, Blazar BR, Weisdorf DJ, MacMillan ML.

Biol Blood Marrow Transplant. 2019 Jul 17. pii: S1083-8791(19)30449-5. doi: 10.1016/j.bbmt.2019.07.017. [Epub ahead of print]

PMID:
31325587
7.

Validation of Minnesota acute graft-versus-host disease Risk Score.

MacMillan ML, DeFor TE, Holtan SG, Rashidi A, Blazar BR, Weisdorf DJ.

Haematologica. 2019 Jul 18. pii: haematol.2019.220970. doi: 10.3324/haematol.2019.220970. [Epub ahead of print]

8.

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.

Cooley S, He F, Bachanova V, Vercellotti GM, DeFor TE, Curtsinger JM, Robertson P, Grzywacz B, Conlon KC, Waldmann TA, McKenna DH, Blazar BR, Weisdorf DJ, Miller JS.

Blood Adv. 2019 Jul 9;3(13):1970-1980. doi: 10.1182/bloodadvances.2018028332.

9.

Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation.

Holtan SG, Zhang L, DeFor TE, Bejanyan N, Arora M, Rashidi A, Lazaryan A, Kotiso F, Blazar BR, Wagner JE, Brunstein CG, MacMillan ML, Weisdorf DJ.

Biol Blood Marrow Transplant. 2019 May 22. pii: S1083-8791(19)30326-X. doi: 10.1016/j.bbmt.2019.05.015. [Epub ahead of print]

PMID:
31128328
10.

Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts.

Ebens CL, McGrath JA, Tamai K, Hovnanian A, Wagner JE, Riddle MJ, Keene DR, DeFor TE, Tryon R, Chen M, Woodley DT, Hook K, Tolar J.

Br J Dermatol. 2019 Mar 6. doi: 10.1111/bjd.17858. [Epub ahead of print]

PMID:
30843184
11.

Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid.

Amin K, Yaqoob U, Schultz B, Vaughn BP, Khoruts A, Howard JR, DeFor TE, Forster C, Meyer C, Gandhi I, Weisdorf DJ, Rashidi A, MacMillan ML, Blazar BR, Panoskaltsis-Mortari A, Holtan SG.

Mod Pathol. 2019 Apr;32(4):560-567. doi: 10.1038/s41379-018-0170-z. Epub 2018 Nov 13.

PMID:
30425334
12.

Influence of Total Body Irradiation Dose Rate on Idiopathic Pneumonia Syndrome in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.

Gao RW, Weisdorf DJ, DeFor TE, Ehler E, Dusenbery KE.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):180-189. doi: 10.1016/j.ijrobp.2018.09.002. Epub 2018 Sep 8.

PMID:
30205123
13.

Predictive value of breast magnetic resonance imaging in detecting mammographically occult contralateral breast cancer: Can we target women more likely to have contralateral breast cancer?

Susnik B, Schneider L, Swenson KK, Krueger J, Braatz C, Lillemoe T, Tsai M, DeFor TE, Knaack M, Rueth N.

J Surg Oncol. 2018 Jul;118(1):221-227. doi: 10.1002/jso.25130. Epub 2018 Sep 9.

PMID:
30196538
14.

Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission.

How J, Vij KR, Ebadi M, DeFor TE, Romee R, Dolan MM, Ustun C, Weisdorf DJ, Linden MA, Rashidi A.

Am J Hematol. 2018 Dec;93(12):E381-E383. doi: 10.1002/ajh.25262. Epub 2018 Oct 9. No abstract available.

PMID:
30144151
15.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, Lee SJ, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Cutler CS, Arai S, Lazaryan A, Newell LF, Jagasia MH, Pusic I, Wood WA, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera YA, Ferrara JLM, Pidala J, Howard A, Wu J, Bolaños-Meade J, Ho V, Alousi A, Blazar BR, Weisdorf DJ, MacMillan ML.

Blood Adv. 2018 Aug 14;2(15):1882-1888. doi: 10.1182/bloodadvances.2018017343.

16.

Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up.

Warlick ED, DeFor TE, Bejanyan N, Holtan S, MacMillan M, Blazar BR, Dusenbery K, Arora M, Bachanova V, Cooley S, Lazaryan A, McGlave P, Miller JS, Rashidi A, Slungaard A, Vercellotti G, Ustun C, Brunsein C, Weisdorf D.

Biol Blood Marrow Transplant. 2019 Jan;25(1):56-62. doi: 10.1016/j.bbmt.2018.07.038. Epub 2018 Aug 1.

PMID:
30077015
17.

Elevations in serum alpha fetoprotein levels in patients with Fanconi anaemia.

Salem B, Mitchell R, DeFor TE, Tryon R, Wagner JE, MacMillan ML.

Br J Haematol. 2019 Mar;184(6):1032-1035. doi: 10.1111/bjh.15223. Epub 2018 Apr 20. No abstract available.

PMID:
29676781
18.

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS.

Blood. 2018 Jun 7;131(23):2515-2527. doi: 10.1182/blood-2017-12-823757. Epub 2018 Feb 20.

19.

Pretransplant Gut Colonization with Intrinsically Vancomycin-Resistant Enterococci (E. gallinarum and E. casseliflavus) and Outcomes of Allogeneic Hematopoietic Cell Transplantation.

Rashidi A, Ebadi M, Shields-Cutler RR, DeFor TE, Al-Ghalith GA, Ferrieri P, Young JH, Dunny GM, Knights D, Weisdorf DJ.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1260-1263. doi: 10.1016/j.bbmt.2018.01.025. Epub 2018 Jan 31.

20.

Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.

Bachanova V, Sarhan D, DeFor TE, Cooley S, Panoskaltsis-Mortari A, Blazar BR, Curtsinger JM, Burns L, Weisdorf DJ, Miller JS.

Cancer Immunol Immunother. 2018 Mar;67(3):483-494. doi: 10.1007/s00262-017-2100-1. Epub 2017 Dec 7.

21.

Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic Anemia.

Ebens CL, DeFor TE, Tryon R, Wagner JE, MacMillan ML.

Biol Blood Marrow Transplant. 2018 Apr;24(4):765-771. doi: 10.1016/j.bbmt.2017.11.031. Epub 2017 Dec 2.

22.

Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402.

Turcotte LM, DeFor TE, Newell LF, Cutler CS, Verneris MR, Wu J, Howard A, MacMillan ML, Antin JH, Vercellotti GM, Slungaard A, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A, Holtan SG.

Bone Marrow Transplant. 2018 Jan;53(1):64-68. doi: 10.1038/bmt.2017.236. Epub 2017 Oct 23.

23.

Operative and survival outcomes in a series of 100 consecutive cases of robot-assisted transhiatal esophagectomies.

Dunn DH, Johnson EM, Anderson CA, Krueger JL, DeFor TE, Morphew JA, Banerji N.

Dis Esophagus. 2017 Oct 1;30(10):1-7. doi: 10.1093/dote/dox045.

PMID:
28859385
24.

Time-to-Event Ratio to Predict Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation?

Ustun C, DeFor TE, Rashidi A, Devine S, Miller J, Weisdorf D.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1804-1808. doi: 10.1016/j.bbmt.2017.06.016. Epub 2017 Jul 5. No abstract available.

25.

History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.

Rashidi A, Linden MA, DeFor TE, Warlick E, Bejanyan N, Yohe S, Weisdorf DJ, Ustun C.

Am J Hematol. 2017 Oct;92(10):1032-1036. doi: 10.1002/ajh.24834. Epub 2017 Jul 29.

26.

Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.

Holtan SG, Newell LF, Cutler C, Verneris MR, DeFor TE, Wu J, Howard A, MacMillan ML, Antin JH, Blazar BR, Weisdorf DJ, Panoskaltsis-Mortari A.

Bone Marrow Transplant. 2017 Sep;52(9):1300-1303. doi: 10.1038/bmt.2017.89. Epub 2017 Jun 5.

27.

Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.

Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, DeFor TE, Malagola M, Anthias C, Valkova V, Kanakry CG, Gruhn B, Buccisano F, Devine B, Walter RB.

Haematologica. 2017 May;102(5):865-873. doi: 10.3324/haematol.2016.159343. Epub 2017 Jan 25. Review.

28.

Allele-Level HLA Matching Impacts Key Outcomes Following Umbilical Cord Blood Transplantation for Inherited Metabolic Disorders.

Mallhi KK, Smith AR, DeFor TE, Lund TC, Orchard PJ, Miller WP.

Biol Blood Marrow Transplant. 2017 Jan;23(1):119-125. doi: 10.1016/j.bbmt.2016.10.019. Epub 2016 Oct 29.

29.

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts.

Brunstein CG, Cutler CS, DeFor TE, Kim H, Bejanyan N, Garfall A, Verneris MR, Chen YB, Warlick ED, Spitzer T, Miller JS, Antin JH, Weisdorf DJ, Soiffer R, Wagner JE, Ballen KK.

Biol Blood Marrow Transplant. 2017 Jan;23(1):126-133. doi: 10.1016/j.bbmt.2016.10.018. Epub 2016 Oct 29.

30.

Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.

Bejanyan N, Rogosheske J, DeFor TE, Lazaryan A, Arora M, Holtan SG, Jacobson PA, MacMillan ML, Verneris MR, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2025-2030. doi: 10.1016/j.bbmt.2016.08.005. Epub 2016 Aug 9.

31.

Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning.

Phelan R, Mann E, Napurski C, DeFor TE, Petryk A, Miller WP, Wagner JE, Verneris MR, Smith AR.

Bone Marrow Transplant. 2016 Oct;51(10):1369-1375. doi: 10.1038/bmt.2016.150. Epub 2016 Jun 6.

32.

BRAF Mutation Is Associated with Improved Local Control of Melanoma Brain Metastases Treated with Gamma Knife Radiosurgery.

Gallaher IS, Watanabe Y, DeFor TE, Dusenbery KE, Lee CK, Hunt MA, Lin HY, Yuan J.

Front Oncol. 2016 May 2;6:107. doi: 10.3389/fonc.2016.00107. eCollection 2016.

33.

Endocrinopathies, Bone Health, and Insulin Resistance in Patients with Fanconi Anemia after Hematopoietic Cell Transplantation.

Barnum JL, Petryk A, Zhang L, DeFor TE, Baker KS, Steinberger J, Nathan B, Wagner JE, MacMillan ML.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1487-1492. doi: 10.1016/j.bbmt.2016.05.004. Epub 2016 May 12.

34.

Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.

Mehta RS, Peffault de Latour R, DeFor TE, Robin M, Lazaryan A, Xhaard A, Bejanyan N, de Fontbrune FS, Arora M, Brunstein CG, Blazar BR, Weisdorf DJ, MacMillan ML, Socie G, Holtan SG.

Haematologica. 2016 Jun;101(6):764-72. doi: 10.3324/haematol.2015.138990. Epub 2016 Apr 1.

35.

Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft.

Wagner JE Jr, Brunstein CG, Boitano AE, DeFor TE, McKenna D, Sumstad D, Blazar BR, Tolar J, Le C, Jones J, Cooke MP, Bleul CC.

Cell Stem Cell. 2016 Jan 7;18(1):144-55. doi: 10.1016/j.stem.2015.10.004. Epub 2015 Dec 5.

36.

Novel disease burden assessment predicts allogeneic transplantation outcomes in myelodysplastic syndrome.

Trottier BJ, Sachs Z, DeFor TE, Shune L, Dolan M, Weisdorf DJ, Ustun C, Warlick ED.

Bone Marrow Transplant. 2016 Feb;51(2):199-204. doi: 10.1038/bmt.2015.274. Epub 2015 Nov 23.

37.

Nonparametric methods for analyzing recurrent gap time data with application to infections after hematopoietic cell transplant.

Lee CH, Luo X, Huang CY, DeFor TE, Brunstein CG, Weisdorf DJ.

Biometrics. 2016 Jun;72(2):535-45. doi: 10.1111/biom.12439. Epub 2015 Nov 17.

38.

Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.

Brunstein CG, Miller JS, McKenna DH, Hippen KL, DeFor TE, Sumstad D, Curtsinger J, Verneris MR, MacMillan ML, Levine BL, Riley JL, June CH, Le C, Weisdorf DJ, McGlave PB, Blazar BR, Wagner JE.

Blood. 2016 Feb 25;127(8):1044-51. doi: 10.1182/blood-2015-06-653667. Epub 2015 Nov 12.

39.

Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation.

Brunstein CG, Petersdorf EW, DeFor TE, Noreen H, Maurer D, MacMillan ML, Ustun C, Verneris MR, Miller JS, Blazar BR, McGlave PB, Weisdorf DJ, Wagner JE.

Biol Blood Marrow Transplant. 2016 Mar;22(3):487-92. doi: 10.1016/j.bbmt.2015.09.025. Epub 2015 Sep 30.

40.

CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT.

Cichocki F, Cooley S, Davis Z, DeFor TE, Schlums H, Zhang B, Brunstein CG, Blazar BR, Wagner J, Diamond DJ, Verneris MR, Bryceson YT, Weisdorf DJ, Miller JS.

Leukemia. 2016 Feb;30(2):456-63. doi: 10.1038/leu.2015.260. Epub 2015 Sep 29.

41.

Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation.

Davis ZB, Cooley SA, Cichocki F, Felices M, Wangen R, Luo X, DeFor TE, Bryceson YT, Diamond DJ, Brunstein C, Blazar BR, Wagner JE, Weisdorf DJ, Horowitz A, Guethlein LA, Parham P, Verneris MR, Miller JS.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1653-62. doi: 10.1016/j.bbmt.2015.05.025. Epub 2015 Jun 6.

42.

Alternative donor hematopoietic cell transplantation for Fanconi anemia.

MacMillan ML, DeFor TE, Young JA, Dusenbery KE, Blazar BR, Slungaard A, Zierhut H, Weisdorf DJ, Wagner JE.

Blood. 2015 Jun 11;125(24):3798-804. doi: 10.1182/blood-2015-02-626002. Epub 2015 Mar 30.

43.

Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.

Holtan SG, Verneris MR, Schultz KR, Newell LF, Meyers G, He F, DeFor TE, Vercellotti GM, Slungaard A, MacMillan ML, Cooley SA, Blazar BR, Panoskaltsis-Mortari A, Weisdorf DJ.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1029-36. doi: 10.1016/j.bbmt.2015.02.018. Epub 2015 Mar 7.

44.

Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.

Ustun C, Trottier BJ, Sachs Z, DeFor TE, Shune L, Courville EL, Holtan SG, Dolan M, Weisdorf DJ, Warlick ED.

Biol Blood Marrow Transplant. 2015 May;21(5):866-72. doi: 10.1016/j.bbmt.2015.01.017. Epub 2015 Jan 22.

45.

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.

Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, Blazar BR, MacMillan ML, Weisdorf DJ.

Blood. 2015 Feb 19;125(8):1333-8. doi: 10.1182/blood-2014-10-609032. Epub 2015 Jan 15.

46.

A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.

MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolaños-Meade J, Ferrara JL, Jones R, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ.

Biol Blood Marrow Transplant. 2015 Apr;21(4):761-7. doi: 10.1016/j.bbmt.2015.01.001. Epub 2015 Jan 10.

47.

The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML.

Hagen P, Wagner JE, DeFor TE, Dolan M, Arora M, Warlick E, Weisdorf D, Brunstein CG.

Bone Marrow Transplant. 2014 Dec;49(12):1498-504. doi: 10.1038/bmt.2014.183. Epub 2014 Sep 22.

48.

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, McGlave P, Weisdorf DJ, Blazar BR, Miller JS.

Blood. 2014 Jun 19;123(25):3855-63. doi: 10.1182/blood-2013-10-532531. Epub 2014 Apr 9.

49.

Donor-derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response.

Dietz AC, DeFor TE, Brunstein CG, Wagner JE Jr.

Br J Haematol. 2014 Jul;166(2):209-12. doi: 10.1111/bjh.12847. Epub 2014 Mar 25.

50.

Newborn screening for X-linked adrenoleukodystrophy: further evidence high throughput screening is feasible.

Theda C, Gibbons K, Defor TE, Donohue PK, Golden WC, Kline AD, Gulamali-Majid F, Panny SR, Hubbard WC, Jones RO, Liu AK, Moser AB, Raymond GV.

Mol Genet Metab. 2014 Jan;111(1):55-7. doi: 10.1016/j.ymgme.2013.10.019. Epub 2013 Nov 9.

Supplemental Content

Loading ...
Support Center